Business Description
OmniAb Inc
NAICS : 541714
SIC : 2834
ISIN : US68218J1034
Total Employee Number:
89Description
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.75 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.77 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.08 | |||||
Beneish M-Score | -1.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38.1 | |||||
3-Year EBITDA Growth Rate | -61.8 | |||||
3-Year EPS without NRI Growth Rate | -29.9 | |||||
3-Year FCF Growth Rate | -10.3 | |||||
3-Year Book Growth Rate | -14.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.84 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 40.93 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 93.91 | |||||
9-Day RSI | 90.86 | |||||
14-Day RSI | 85.69 | |||||
3-1 Month Momentum % | -2.75 | |||||
6-1 Month Momentum % | 23.98 | |||||
12-1 Month Momentum % | 5.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.8 | |||||
Quick Ratio | 4.72 | |||||
Cash Ratio | 3.78 | |||||
Days Inventory | 436.02 | |||||
Days Sales Outstanding | 68.64 | |||||
Days Payable | 1046.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.8 | |||||
Shareholder Yield % | 0.51 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.28 | |||||
Operating Margin % | -125.78 | |||||
Net Margin % | -115.12 | |||||
EBITDA Margin % | -63.91 | |||||
FCF Margin % | -47.17 | |||||
OCF Margin % | -45.95 | |||||
ROE % | -16.65 | |||||
ROA % | -14.85 | |||||
ROIC % | -18.89 | |||||
3-Year ROIIC % | 59.03 | |||||
ROC (Joel Greenblatt) % | -169.39 | |||||
ROCE % | -17.02 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.8 | |||||
PB Ratio | 2.15 | |||||
Price-to-Tangible-Book | 9.4 | |||||
EV-to-EBIT | -10.9 | |||||
EV-to-Forward-EBIT | -10.97 | |||||
EV-to-EBITDA | -21.46 | |||||
EV-to-Forward-EBITDA | -10.97 | |||||
EV-to-Revenue | 13.71 | |||||
EV-to-Forward-Revenue | 14.8 | |||||
EV-to-FCF | -29.07 | |||||
Price-to-GF-Value | 1.32 | |||||
| Price-to-Net-Current-Asset-Value | 15.42 | |||||
| Price-to-Net-Cash | 25.7 | |||||
Earnings Yield (Greenblatt) % | -9.17 | |||||
FCF Yield % | -3.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OABI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OmniAb Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.457 | ||
| EPS (TTM) ($) | -0.36 | ||
| Beta | 1.7603 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 104.55 | ||
| 14-Day RSI | 85.69 | ||
| 14-Day ATR ($) | 0.255668 | ||
| 20-Day SMA ($) | 2.516 | ||
| 12-1 Month Momentum % | 5.47 | ||
| 52-Week Range ($) | 1.3 - 4.2899 | ||
| Shares Outstanding (Mil) | 145.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OmniAb Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OmniAb Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 79 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 78 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 2.03 (+1.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 2.03 (+1.00%) | ||
| General meeting for 2026 | 2026-06-17 08:00 | 2.02 (-4.27%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 1.43 (+2.14%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.43 (+2.14%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-04 16:30 | 1.73 (+0.58%) | ||
| Annual report for 2025 | 2026-03-04 | 1.73 (+0.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 1.73 (+0.58%) |
Show
Entries
OmniAb Inc Frequently Asked Questions
What is OmniAb Inc(OABI)'s stock price today?
The current price of OABI is $3.86. The 52 week high of OABI is $4.29 and 52 week low is $1.30.
When is next earnings date of OmniAb Inc(OABI)?
The next earnings date of OmniAb Inc(OABI) is 2026-11-04 Est..
Does OmniAb Inc(OABI) pay dividends? If so, how much?
OmniAb Inc(OABI) does not pay dividend.
Guru Commentaries on NAS:OABI
No articles.
Press Release
Articles on OmniAb Inc
Headlines
See More- 1
Aug 17, 2026
OmniAb signs up to $370M licensing deal with Eli Lilly for ion channel program
Seeking Alpha • 5:08am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers